Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease

Authors not listed

AbbVie (prior sponsor, Abbott) · 2009

Dysbiosis Human Randomized controlled trial

＋ Sign in to save

Abstract

This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-11 MST

Cite this

APA

Anonymous. (2009). A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease. <em>AbbVie (prior sponsor, Abbott)</em>. https://clinicaltrials.gov/study/NCT00948909

Vancouver

Anonymous. A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease. AbbVie (prior sponsor, Abbott). 2009.

BibTeX

@misc{anon2009ARando, title = {A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease}, author = {Anonymous}, journal = {AbbVie (prior sponsor, Abbott)}, year = {2009}, }